Site notes
This page validates as XHTML 1.0, and will look much better in a browser that supports web standards. So maybe you should...
This page validates as XHTML 1.0, and will look much better in a browser that supports web standards. So maybe you should...
Sender's message:
Sent on Saturday, 2007 Sep 01.
Search breast cancer
Click on the following url to view complete results in pubmed. (Results may change over time.)
http://www.ncbi.nlm.nih.gov/entrez/cubby.fcgi?call=0hrJlNdx_wzM6yfTudNWJUuvWuJuGaSxVnfM9D8OpDRm32f7TdUH-0-0gBVQT3j&WebCubbyUser=0DGBW02BQTeT39ex8EgLs_M5%401FC049396DA29500_0040SID
To unsubscribe from these e-mail updates click on the following url
http://www.ncbi.nlm.nih.gov/entrez/cubby.fcgi?call=0HihbofO4ofXLFhrM34zLFkxKe6vPE28Zxx-o4wbpVJRBcJJV&WebCubbyUser=0DGBW02BQTeT39ex8EgLs_M5%401FC049396DA29500_0040SID
==================== Entrez pubmed Results ======================
Items 1 - 5 of 52
1: Cancer. 2007 Aug 30; [Epub ahead of print]
Pathologic fractures correlate with reduced survival in patients with malignant
bone disease.
Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R.
Centre Hospitalier de l'Universite de Montreal, Hopital Notre-Dame, Montreal,
Quebec, Canada.
BACKGROUND.: Data from randomized, controlled trials of zoledronic acid were
retrospectively analyzed to assess the effect of pathologic fractures on
survival in patients with malignant bone disease. METHODS.: A Cox regression
model was used to estimate the effect of fractures (time-dependent variable) on
survival in patients with stage III multiple myeloma or bone metastases from
solid tumors enrolled in 3 large trials. Patients were randomized to receive
zoledronic acid, pamidronate, or placebo every 3-4 weeks for up to 24 months
(prostate cancer, breast cancer, and multiple myeloma) or up to 21 months (lung
and other solid tumors). RESULTS.: A total of 3049 patients with multiple
myeloma (n = 513), breast (n = 1130), prostate (n = 640), or lung cancer or
other solid tumors (n = 766) were included in this analysis. Patients with
multiple myeloma had the highest fracture incidence (43%), followed by breast
(35%), prostate (19%), and lung cancer (17%). In all tumor types except lung,
pathologic fracture was associated with a significant increase in risk of death,
and breast cancer patients had the greatest increased risk. After adjustment for
baseline characteristics, including performance status and prior skeletal
complications, breast cancer patients who developed a pathologic fracture on
study had a significant 32% increased risk of death relative to patients without
a fracture (hazard ratio = 1.32; P < .01); patients with multiple myeloma or
prostate cancer had a >20% increased risk of death. CONCLUSIONS.: These results
suggest that fractures are associated with increased risk of death in patients
with malignant bone disease. Therefore, preventing fractures is an important
goal of therapy. Cancer 2007. (c) 2007 American Cancer Society.
PMID: 17763372 [PubMed - as supplied by publisher]
2: Cancer. 2007 Aug 30; [Epub ahead of print]
Breast cancer vaccines: promise for the future or pipe dream?
Mittendorf EA, Peoples GE, Singletary SE.
Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer
Center, Houston, Texas.
The objective of this study was to review issues involved in the search for a
breast cancer vaccine. A review of the recent literature (2004-2007) was
undertaken, with earlier literature included as appropriate for background, to
assess 1) current approaches being used to create a therapeutic breast cancer
vaccine, and 2) potential strategies for a preventive vaccine targeting either
an infectious agent or tumor-associated antigen. Several approaches to the
development of a therapeutic vaccine show promise, including tumor
cell/dendritic cell fusion and DNA vaccines based on single purified antigens or
DNA fragments from whole cells. Most of these experimental vaccines have either
not moved beyond preclinical testing or have not shown a significant clinical
response. Strategies involving host factors that mitigate immune response
against tumors also show promise. Interest has increased in developing a
preventive vaccine that can be administered to immunocompetent patients with
minimal or no evidence of disease. Prophylactic vaccines typically target
infectious agents, but the evidence for an infectious etiology for breast cancer
is largely descriptive and difficult to interpret. A second strategy for a
preventive breast cancer vaccine is to target tumor-associated antigens. Ongoing
clinical trials are utilizing this approach, with preliminary results that are
encouraging. Cancer 2007. (c) 2007 American Cancer Society.
PMID: 17763371 [PubMed - as supplied by publisher]
3: Cancer. 2007 Aug 30; [Epub ahead of print]
Prospective assessment of radiotherapy-associated cardiac toxicity in breast
cancer patients: Analysis of data 3 to 6 years after treatment.
Prosnitz RG, Hubbs JL, Evans ES, Zhou SM, Yu X, Blazing MA, Hollis DR, Tisch A,
Wong TZ, Borges-Neto S, Hardenbergh PH, Marks LB.
Department of Radiation Oncology, Duke University Medical Center, Durham, North
Carolina.
BACKGROUND.: Radiation therapy (RT) to the left breast/chest wall has been
linked with cardiac dysfunction. Previously, the authors identified cardiac
perfusion defects in approximately 50% to 60% of patients 0.5 to 2 years
post-RT. In the current study, they assessed the persistence of these defects 3
to 6 years post-RT. METHODS.: From 1998 to 2006, 160 patients with left-sided
breast cancer were enrolled onto an Institutional Review Board-approved,
prospective study. All patients received tangential photons to the left
breast/chest wall. Patients had pre-RT and serial post-RT single-photon emission
computed tomography (SPECT) scans to assess changes in regional cardiac
perfusion, wall motion, and ejection fraction (EF). Forty-four patients had
SPECT scans 3 to 6 years post-RT and were evaluable for the current analysis.
RESULTS.: The overall incidence of perfusion defects at 3 years, 4 years, 5
years, and 6 years was 52% (11 of 21 patients), 71% (17 of 24 patients), 67% (12
of 18 patients), and 57% (4 of 7 patients), respectively. The rate of abnormal
SPECT scans 3 to 6 years post-RT in patients who had scans at 0.5 to 2 years
that were either all abnormal, intermittently abnormal, or all normal was 80%,
67%, and 63%, respectively. The incidence of wall motion abnormalities in
patients with or without perfusion defects 3 to 6 years post-RT was low and did
not differ statistically (17% vs 7.1%, respectively; P = .65), as was the
incidence of reductions in EF of >/=5% (27% vs 36%, respectively; P = .72).
CONCLUSIONS.: The results from this study indicated that RT-induced perfusion
defects may persist or initially may appear 3 to 6 years post-RT in a high
percentage of patients. However, these defects were not associated with changes
in regional wall motion or EF. Additional study will be needed to determine the
clinical relevance of these defects. In the meantime, the authors believe that
every effort should be made to minimize incidental irradiation of the heart
while maintaining adequate coverage of target volumes. Cancer 2007. (c) 2007
American Cancer Society.
PMID: 17763369 [PubMed - as supplied by publisher]
4: Ann Surg Oncol. 2007 Aug 29; [Epub ahead of print]
Overexpression of Interleukin-10 in Sentinel Lymph Node with Breast Cancer.
Woo SU, Bae JW, Yang JH, Kim JH, Nam SJ, Shin YK.
Department of Surgery, Korea University College of Medicine, Seoul, Korea.
BACKGROUND: In breast carcinoma, identification of tumor cells in the sentinel
lymph nodes is a predictor of the tumor's metastatic potential. Sentinel lymph
node may be targeted not only by tumor cell metastasis but also by cytokines
from the emergence of antitumor immune responses. METHODS: Between February 2003
and February 2004, the investigator evaluated 38 cases that underwent sentinel
lymph node biopsy at the Samsung Medical Center. Eighty paraffin-embedded
sections, 49 sentinel, and 31 nonsentinel lymph node, from breast carcinoma
without lymphatic metastases were analyzed by real-time polymerase chain
reaction to evaluate the cytokine profile (interferon-gamma, interleukin-2,
interleukin-10 and interleukin-12) for the T cell response. RESULTS: A higher
expression of interleukin-10 was observed in sentinel lymph node than in
nonsentinel lymph node (P = 0.03). The expressions of interferon-gamma,
interleukin-2, and interleukin-12 were similar between sentinel and nonsentinel
lymph node. CONCLUSIONS: Theses results indicate that T cell response was
downregulated by interleukin-10 overexpression in sentinel lymph node with
breast cancer.
PMID: 17762971 [PubMed - as supplied by publisher]
5: Am J Clin Oncol. 2007 Aug;30(4):432-6.
Multivitamins do not improve radiation therapy-related fatigue: results of a
double-blind randomized crossover trial.
de Souza Fede AB, Bensi CG, Trufelli DC, de Oliveira Campos MP, Pecoroni PG,
Ranzatti RP, Kaliks R, Del Giglio A.
Faculdade de Medicina do ABC Foundation School of Medicine, ABC Foundation
School of Medicine, Sao Paulo, Brazil.
BACKGROUND: Fatigue is a common symptom in cancer patients receiving radiation
therapy. PATIENTS AND METHODS: We conducted a double-blind randomized crossover
trial of multivitamins versus placebo in patients with breast cancer undergoing
radiation therapy to evaluate fatigue and quality of life. RESULTS:: We
randomized 40 patients to either placebo or Centrum Silver. At the middle of the
radiation treatments, patients were switched from placebo to multivitamins and
vice versa. Patients answered the EORTC QLQ C-30 quality of life (QOL) and
Chalder fatigue questionnaires at the beginning, middle, and end of radiation
therapy. Both groups experienced decreases in general (P = 0.009; P = 0.001) and
physical fatigue scores (P = 0.031; P = 0.029) at the end of the course of
placebo compared with the assessment prior to this treatment. We also observed
significant improvements in functional (P = 0.026) and symptoms (P = 0.016)
score scales of the QOL questionnaire in the patients on placebo. No significant
changes were elicited with the use of multivitamins. We also observed
significantly lower rates of fatigue in the patients who had just finished a
course of placebo as compared with patients finishing a course of multivitamins
(0 vs. 25% P = 0.035). CONCLUSION: Multivitamins do not improve
radiation-related fatigue in patients with breast cancer.
PMID: 17762445 [PubMed - in process]